Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00131937).
- Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer: Complete Statistical AnalysisIndependent statistical analysis of Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Southwest Harvest for Health Vegetable Gardening Intervention: Complete Statistical AnalysisIndependent statistical analysis of Southwest Harvest for Health Vegetable Gardening Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04251299).
- Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery: Complete Statistical AnalysisIndependent statistical analysis of Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery: primary endpoint results, effect estimate with confidence interval,…
- Soy Protein and Breast Cancer Risk Reduction: Complete Statistical AnalysisIndependent statistical analysis of Soy Protein and Breast Cancer Risk Reduction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00204477).
- Soy Protein/Effexor Hormone Therapy for Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Soy Protein/Effexor Hormone Therapy for Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00354432).
- SP-RLBIndependent statistical analysis of The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- SP0993Independent statistical analysis of Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older: primary endpoint results, effect estimate with…
- SPARKIndependent statistical analysis of Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- SPARK Symptom Screening and Feedback to Providers: Complete Statistical AnalysisIndependent statistical analysis of SPARK Symptom Screening and Feedback to Providers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03593525).
- SPARTAIndependent statistical analysis of Spinery® A Novel Radio-Frequency Tumor Ablation Device for Spine Metastatic Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SPARTANIndependent statistical analysis of Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SPARTANIndependent statistical analysis of A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SPARXIndependent statistical analysis of Study in Parkinson's Disease of Exercise: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01506479).
- SPDPIndependent statistical analysis of The Stanford Parkinson's Disease Plasma Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02968433).
- SPEACIndependent statistical analysis of Study of a PST-Trained Voice-Enabled Artificial Intelligence Counselor(SPEAC) for Adults With Emotional Distress (Phase 2): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion “Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma”: Complete Statistical AnalysisIndependent statistical analysis of Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma": primary endpoint results, effect estimate with confidence…
- Special Drug Use Surveillance of Vonoprazan for “Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use”: Complete Statistical AnalysisIndependent statistical analysis of Special Drug Use Surveillance of Vonoprazan for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use": primary endpoint results, effect estimate with confidence…
- Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis: Complete Statistical AnalysisIndependent statistical analysis of Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Special Survey on Parkinson’s Disease (PD) Patients Without Concomitant Use of L-Dopa: Complete Statistical AnalysisIndependent statistical analysis of Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Specialized Pacing for Patients With Congenital Heart Disease: Complete Statistical AnalysisIndependent statistical analysis of Specialized Pacing for Patients With Congenital Heart Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03361189).
- Specified Drug-Use Survey of Trelagliptin Tablets “Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease”: Complete Statistical AnalysisIndependent statistical analysis of Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease": primary endpoint results, effect…
- SPECSIndependent statistical analysis of SPECS: Safe Pediatric Euglycemia in Cardiac Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00443599).
- Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC: Complete Statistical AnalysisIndependent statistical analysis of Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With ABC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy: Complete Statistical AnalysisIndependent statistical analysis of SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Spectral Dynamics and Speech Understanding by Hearing Impaired People: Complete Statistical AnalysisIndependent statistical analysis of Spectral Dynamics and Speech Understanding by Hearing Impaired People: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01867515).
- SPECTREMIndependent statistical analysis of Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Spectroscopy Versus Standard Care in Cervical Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Spectroscopy Versus Standard Care in Cervical Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00529464).
- SPECTRUMIndependent statistical analysis of Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Speech Processing in Stuttering: Complete Statistical AnalysisIndependent statistical analysis of Speech Processing in Stuttering: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04929184).
- SPEEDIndependent statistical analysis of Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SPEEDIndependent statistical analysis of Bridge to Orthotopic Liver Transplantation (OLT) - Surefire Precision vs Endhole Embolization With DEBTACE: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery: Complete Statistical AnalysisIndependent statistical analysis of Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02978690).
- Spesolimab in Pyoderma Gangrenosum: Complete Statistical AnalysisIndependent statistical analysis of Spesolimab in Pyoderma Gangrenosum: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06092216).
- SPGblockIndependent statistical analysis of Sphenopalatine Ganglion Blocks RCT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03666663).
- Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines: Complete Statistical AnalysisIndependent statistical analysis of Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SPI2Independent statistical analysis of Effect of MD1003 in Progressive Multiple Sclerosis (SPI2): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02936037).
- SPICEIndependent statistical analysis of Curcumin and Function in Older Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03085680).
- SPIDEPIndependent statistical analysis of Spinal Cord Stimulation for the Treatment of Major Depressive Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03433339).
- sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS: Complete Statistical AnalysisIndependent statistical analysis of sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02239562).
- Spinal Anesthesia Induced Hypotension During Cesarean Section: Complete Statistical AnalysisIndependent statistical analysis of Spinal Anesthesia Induced Hypotension During Cesarean Section: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00846651).
- SPINETIndependent statistical analysis of Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- SPIRE-1Independent statistical analysis of The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- SPIRE-2Independent statistical analysis of The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- SPIRITIndependent statistical analysis of Antiarrhythmic Effects of Spironolactone in Patients With ICDs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04495712).